Incidence and influencing factors of favipiravir-associated serum uric acid elevation in patients with coronavirus disease 2019
10.3760/cma.j.cn114015-20211025-01095
- VernacularTitle:新型冠状病毒肺炎患者法维拉韦相关血尿酸升高的发生情况及影响因素分析
- Author:
Fang QIAN
1
;
Yanli XU
1
;
Meihua SONG
1
;
Di TIAN
1
;
Xingxiang REN
1
;
Ziruo GE
1
;
Tingyu ZHANG
1
;
Aibin WANG
1
;
Bing HAN
1
;
Zhihai CHEN
1
Author Information
1. 首都医科大学附属北京地坛医院感染性疾病诊疗中心，感染病科国家临床重点专科，北京 100015
- Publication Type:Journal Article
- Keywords:
COVID-19;
Uric acid;
Hyperuricemia;
Drug-related side effects and adverse reactions;
Favipiravir
- From:
Adverse Drug Reactions Journal
2022;24(4):169-174
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the occurrence and influencing factors of serum uric acid elevation in patients with coronavirus disease 2019 (COVID-19) treated with favipiravir.Methods:Medical records of patients with COVID-19 who were hospitalized in Beijing Ditan Hospital between June 1, 2020 and June 30, 2021 and treated with the 5- or 10-day regimen of favipiravir were collected and retrospectively analyzed. After favipiravir withdrawal, if the elevation in serum uric acid was ≥30% of baseline level, it was defined as serum uric acid elevation. Then patients were divided into serum uric acid elevation group and non-serum uric acid elevation group. The clinical characteristics such as gender, age, body mass index, comorbidities, smoking and drinking behavior, COVID-19 grade, favipiravir regimen, and serum uric acid level and renal function before treatment in patients between the 2 groups were compared. Influencing factors of favipiravir-associated serum uric acid elevation was analyzed using multivariate logistic regression method.Results:A total of 179 patients were included in the analysis, including 104 (58.1%) males and 75 (41.9%) females, aged from 19 to 70 years with a median age of 43 years. The level of serum uric acid in 179 patients after favipiravir treatment was significantly higher than before [(451±119) μmol/L vs. (332±94) μmol/L, P<0.001]. The change rate of serum uric acid from baseline level ranged from -57.1% to 157.8% with the median of 38.6%. The elevation in serum uric acid of ≥ 30% of baseline level occurred in 108 (60.3%) patients. The incidences of serum uric acid elevation in patients treated with 5-day and 10-day regimens of favipiravir were 46.8% (36/77) and 70.6% (72/102), respectively, and the difference between them was significant ( P=0.001). Multivariate logistic regression analysis showed that body mass index 24.0 to <28.0 kg/m 2 ( OR=3.109, 95 %CI: 1.209-7.994, P=0.019) and 10-day regimen of favipiravir ( OR=3.017, 95 %CI: 1.526-5.964, P=0.001) were independent risk factors for favipiravir-associated serum uric acid elevation. Conclusions:More than half of COVID-19 patients treated with favipiravir can develop serum uric acid elevation. Overweight and 10-day regimen of favipiravir are independent risk factors for serum uric acid elevation in patients.
